48 results about "Mogroside V" patented technology

The invention discloses a method for efficient conversion and utilization of mogroside. According to the method, mogroside V is converted through fermentation of candida parapsilosis L7, and siamenoside I is directionally synthesized. According to the invention, Candida parapsiloides L7 is utilized for fermentation conversion, and beta-1, 6-glucosidic bonds in glucose branched chains connected with C3-site hydroxyl of a mogroside V structure parent nucleus can be directionally hydrolyzed with high regioselectivity (the beta-1, 6-glucosidic bonds on glucose branched chains connected with C24-site hydroxyl are hardly hydrolyzed), so that one molecule of glucose is removed, and siamenoside I is obtained. The siamenoside I provided by the invention can be efficiently prepared, and the maximum molar yield of the siamenoside I can reach 87.40%. The siamenoside I has more obvious selective hydrolysis characteristic, higher space time yield of the siamenoside I, no cytotoxicity of the siamenoside I and better anti-inflammatory and antioxidant activity, provides a new drug choice for diseases such as inflammation and the like, and provides technical support for development of high-valued products of mogroside.

The invention relates to a stevioside composition, which comprises at least one stevioside and at least one of siamenoside I, mogroside V, mogroside III-E and mogroside II-E, and is characterized in that the stevioside composition comprises at least one stevioside and at least one of siamenoside I, mogroside V, mogroside III-E and mogroside II-E; wherein the stevioside has a higher solubility in the composition than in an equivalent composition lacking siamenoside I, mogroside V, mogroside III-E, and mogroside II-E. The invention also relates to a method for preparing the stevioside composition. The composition may be an aqueous solution.

The invention discloses saccharomyces cerevisiae engineering bacteria for efficiently synthesizing mogroside V on the basis of cytoplasm and lipid droplet double-cell area compartment and a construction method of the saccharomyces cerevisiae engineering bacteria. The construction method comprises the following steps: integrating truncated 3-hydroxy-3-methylglutaryl coenzyme A reductase tHMG1, pentenyl pyrophosphate isomerase IDI1, epoxy squalene cyclization enzyme ERG1, squalene synthetase ERG9, choline kinase ScCK, isopentenyl phosphokinase AtIPK, cucurbitadienol synthetase SgCDS, cyclic epoxy hydrolase SgEPH3, cytochrome P450 enzyme CYP87D18 and cytochrome P450 enzyme reductase AtCPR1 at the site of a saccharomyces cerevisiae genome GAL80; an ABC efflux protein PDR11, a glycosyl transferase UGTMG1, a sucrose synthase Susy and a glycosyl transferase SgUGT94-289-3 are integrated at a site Exg1 of a saccharomyces cerevisiae genome. The yield of mogroside V produced by shake flask fermentation of the saccharomyces cerevisiae engineering strain provided by the invention reaches 96.3 mg / L, so that mogroside V is efficiently synthesized from the beginning in the saccharomyces cerevisiae, and the saccharomyces cerevisiae engineering strain has important practical significance for promoting sustainable development of the mogroside industry.

The invention provides a pulmonary nodule targeting food and medicine homologous composition based on metabonomics screening and application thereof. By analyzing a pulmonary nodule specific metabolic profile, active components, namely platycodin D, mogroside V, oyster active peptide and fermented cordycepin, which can cooperatively regulate and control an arachidonic acid inflammation pathway, a glutathione antioxidant pathway and a tricarboxylic acid cycle energy pathway are reversely screened out. Animal experiments prove that the composition can reduce the volume of pulmonary nodules by 58.3%, human body application shows that the nodules of 76.7% of subjects are reduced, and liver and kidney toxicity is avoided. The composition can be prepared into tablets, capsules and other dosage forms, can be used as functional food or adjuvant therapy drugs for high risk groups of pulmonary nodules, and realizes accurate nutrition intervention.

The invention discloses a preparation method of mogroside, which comprises the following steps: taking fresh siraitia grosvenorii pulp, and carrying out flash extraction with alkaline water at the temperature of 10-15 DEG C; placing the treated pulp in a flash extractor, extracting twice in a solvent, and combining filtrates extracted twice to obtain a total filtrate; performing composite column chromatography on the total filtrate, eluting with pure water, combining the collected effluent and water washing liquid, and concentrating the solution; adding high-activity yeast into the obtained solution, fermenting for 4-6 hours at the temperature of 30-32 DEG C, then inactivating, cooling, filtering, passing through macroporous resin chromatography, sequentially eluting with pure water, acetone and ethanol, collecting ethanol eluant, and concentrating at low temperature to obtain concentrated solution; and adding pure methanol or absolute ethyl alcohol into the obtained concentrated solution, crystallizing under sealing and stirring conditions, carrying out suction filtration to obtain crystals, washing, dissolving with pure water, concentrating, and carrying out spray drying to obtain the mogroside. According to the method, the mogroside product with few impurities and high mogroside V content can be obtained.

The invention discloses a saccharomyces cerevisiae genetically engineered bacterium for efficiently synthesizing mogroside V based on multi-compartment multi-metabolic pathways and a construction method of the saccharomyces cerevisiae genetically engineered bacterium. The preparation method comprises the following steps: anchoring an MVA pathway and a squalene synthesis pathway on the surface of a peroxisome membrane, and enabling mogrol synthetase and epoxy squalene cyclization enzyme ERG1 to form a linear polywheat complex through polypeptide interaction; then, through overexpression of MVA pathway key enzyme and introduction of an isopentenol utilization pathway, supply of precursor isopentenyl pyrophosphate and dimethyl allyl pyrophosphate in cytoplasm is increased, and squalene epoxidase ERG1 and mogrol synthetase are anchored in transmembrane ABC efflux protein PDR11 through polypeptide interaction; then anchoring the mogrol synthetase in the lipid droplet subcells; finally, the glucosyltransferase is displayed on the surface of the yeast cell wall through an alpha-lectin system, so that extracellular mogrol is converted into MG-V. The engineering bacterium improves the yield of mogroside V synthesized from the beginning in microorganisms, and has great industrial application value.

To provide alternative and / or improved sweetness modifying composition.SOLUTION: There is provided a sweetness modifying composition comprising: one or more high-intensity sweetener(s) selected from steviol glycosides and / or mogrosides; and one or more low-intensity sweetener(s) selected from cellobiose, psicose, cyclamate and / or 11-O-mogroside V, wherein the sweetness modifying composition increases the sweetness of a sweetened composition by more than the sweetness of the sweetness modifying composition alone; and / or wherein the ratio of the one or more high-intensity sweetener(s) to the one or more low-potency sweetener(s) ranges from about 2:1 to about 12:1.SELECTED DRAWING: None

The present disclosure provides compositions and methods for Agrobacterium infiltration of plant tissues, for example fruit, vegetable or leaf tissues, and the use of such plant tissues for production of high-value compounds, for example mogroside compounds, in particular mogroside V, betalain, lactoferrin, or fluorescent proteins, such as green fluorescent protein (GFP), and the high-value compounds so produced.

The invention discloses a siraitia grosvenorii variety quality typing accurate identification method and model, and belongs to the technical field of medicinal material detection.The siraitia grosvenorii variety quality typing accurate identification method comprises the steps that 1, siraitia grosvenorii saponin quality indexes of a plurality of varieties are detected; the method comprises the following steps of: acquiring four main key content indexes, namely 11-O-mogroside V (11-O-MV), mogroside V (MV), isomogroside V (IMV) and siamenoside I (SI) in the momordica grosvenori, as well as a total saponin content index and a sweetness data index; step 2, carrying out clustering processing on the obtained mogroside content and sweetness data to generate a plurality of clustering categories; step 3, establishing a corresponding relationship between the quality of the siraitia grosvenorii variety and the siraitia grosvenorii saponin content and sweetness clustering category; and step 4, based on the established corresponding relationship, performing variety quality typing identification on the to-be-detected siraitia grosvenorii sample. According to the method, the efficiency and the precision degree of the siraitia grosvenorii variety quality typing identification can be improved.

The present disclosure provides compositions and methods for producing transgenic plants and other organisms that exhibit increased production of mogroside compounds, in particular mogroside V, and the mogroside compounds, plants and plant parts so produced.

The present invention provides host cells and methods for making mogrol glycosides, including Mogroside V (Mog.V), Mogroside VI (Mog.VI), Iso-Mogroside V (Isomog.V), siamenoside, and glycosylation products that are minor products in Siraitia grosvenorii. The invention provides engineered enzymes and engineered host cells for producing mogrol glycosylation products, such as Mog.V, Mog.VI, and Isomog.V, at high purity and / or yield. The present technology further provides methods of making products containing mogrol glycosides, such as Mog.V, Mog.VI, and Isomog.V, including food products, beverages, oral care products, sweeteners, and flavoring products.

The invention discloses saccharomyces cerevisiae engineering bacteria for efficiently synthesizing mogroside V based on lipid droplet subcellular organelles and a construction method of the saccharomyces cerevisiae engineering bacteria. The construction method comprises the following steps: integrating squalene epoxidase ERG1, cucurbitadienol synthetase SgCDS, cyclic epoxy hydrolase SgEPH3, cytochrome P450 enzyme CYP87D18 and cytochrome P450 enzyme reductase AtCPR1 at a site GAL80 of a saccharomyces cerevisiae genome; the saccharomyces cerevisiae strain is characterized in that phosphoglucose mutase PGM1, alpha-phosphoglucose mutase PGM2, uridine diphosphate glucose pyrophosphorylase UGP1, glycosyl transferase UGTMG1 and glycosyl transferase SgUGT94-289-3 are integrated at a site Exg1 of a saccharomyces cerevisiae genome. The Saccharomyces cerevisiae engineering bacterium constructed by the invention realizes that the yield of MG-V synthesized by shake flask fermentation is 31.4 mg / L. The Saccharomyces cerevisiae engineering bacterium has the characteristics of strong metabolic flux directionality, high yield and wide industrial application prospect.

The invention relates to the technical field of cosmetics, in particular to application of mogroside V in preparation of skin barrier repair cosmetics, the mogroside V serves as an active ingredient, the purity of the mogroside V is not lower than 30%, and the mogroside V can be prepared into various cosmetic dosage forms such as toning lotion, facial masks and essence cream. The mogroside V has no significant toxicity to keratinocytes, can accelerate skin barrier repair by promoting cell migration, has significant antioxidant activity, and can scavenge free radicals, reduce oxidative stress injury and realize synergistic effects of barrier repair and oxidation resistance and aging resistance. Besides, mogroside V is a natural water-soluble component, can be stably dispersed in a water-based formula without a solubilizer, is free of thick and sticky feeling during use, and solves the problem of skin feeling pain points of traditional repairing components. The barrier damage problems of dry skin, redness, desquamation and the like can be improved in a targeted manner, and the application prospect is wide.

The invention relates to the technical field of cosmetics, in particular to a skin care composition with a skin aging improving function, which comprises mogroside V and a golden camellia extract. The composition can significantly reduce the expression level of aging-related SA-beta-galactosidase in human skin fibroblasts, thereby effectively inhibiting skin cell aging. Mogroside V and the camellia nitidissima extract are compounded to achieve a synergistic effect, and the anti-aging effect of the composition is remarkably superior to that of a single component. The composition is safe and non-irritant, the raw materials are natural, and the composition is suitable for various cosmetic dosage forms such as essence, face cream and facial masks.

The present application relates to a sweet composition, more particularly to a sweet composition and its preparation method and use. The sweet composition comprises at least 0-99% mogroside V and 0-99% fructooligosaccharide. The preparation method comprises taking a mogroside extract, and then performing enzymatic conversion treatment on the mogroside extract by using a biological enzyme coupling membrane separation technology. Under the action of fructose transmembrane enzyme, sucrose enzyme and glucose isomerase, sucrose in the mogroside is converted into fructooligosaccharide, and the generally existing low-sweetness glucose in the mogroside is converted into high-sweetness fructose. Then, after recombination, concentration and sterilization, the sweet composition is obtained. The mogroside sweet composition product prepared by the present application not only has low sugar and low heat, but also has purer taste, fuller flavor, faster dissolution, and is closer to edible sugar. The defects of insufficient sweetness and slow sweetness of mogroside V after sweetness are improved, and the mogroside sweet composition can be applied to the preparation of food, beverage, dietary supplement, medicine and pet food.

The invention discloses a saccharomyces cerevisiae engineering bacterium for efficiently synthesizing mogroside V based on peroxisome and lipid droplet double-cell area compartment and a construction method of the saccharomyces cerevisiae engineering bacterium. According to the construction method disclosed by the invention, squalene epoxidase ERG1 is anchored on the surface of a peroxisome membrane and in lipid droplets respectively; the ERG1 and downstream metabolic enzymes such as cucurbitadienol synthetase, cyclic epoxy hydrolase, cytochrome P450 enzyme, cytochrome P450 enzyme reductase, phosphoglucomutase, alpha-phosphoglucomutase, uridine diphosphate glucose pyrophosphorylase and glycosyltransferase are assembled into a multi-enzyme complex by adopting a multi-enzyme complex directional assembly strategy; the method not only enhances the directionality of metabolic flux, but also improves the catalytic efficiency of the enzyme and reduces the generation of byproducts, thereby realizing efficient synthesis of MG-V.

The invention discloses application of mogroside V in preparation of an anti-renal fibrosis medicine, and belongs to the technical field of biological medicines. Experiments prove that the mogroside V can obviously improve the renal function of a mouse with renal fibrosis, and the serum creatinine and blood urea nitrogen levels are obviously reduced. Meanwhile, the compound can be used for effectively inhibiting the expression of fibrosis markers alpha-SMA and Fibronectin in renal tissues, and delaying the fibrosis process by up-regulating the expression level of an epithelial-mesenchymal transition marker E-cadherin. In addition, the mogroside V can also significantly reduce collagen deposition in kidney tissues, and plays a role in treating renal fibrosis. The traditional Chinese medicine composition has the advantages of safety, effectiveness, no side effect, good taste and the like when being used for preparing the anti-renal fibrosis medicine.

The invention discloses a saccharomyces cerevisiae engineering bacterium for efficiently synthesizing mogroside V based on cytoplasm and peroxisome double-cell-region indoor and a construction method of the saccharomyces cerevisiae engineering bacterium. Wherein the construction method comprises the following steps: integrating acetoacetyl coenzyme A thiolase ERG10, 3-hydroxy-3-methylglutaryl coenzyme A synthetase ERG13, truncated 3-hydroxy-3-methylglutaryl coenzyme A reductase tHMG1, phosphomevalonate kinase ERG8, mevalonate pyrophosphate decarboxylase ERG19, pentenyl pyrophosphate isomerase IDI1 and geranyl pyrophosphate synthase ERG20 at a site of a saccharomyces cerevisiae genome GAL80, and carrying out enzymolysis, so as to obtain a saccharomyces cerevisiae strain; a squalene synthase ERG9, an epoxy squalene cyclization enzyme ERG1 and the like; aBC efflux protein PDR11, isopentene phosphokinase AtIPK, geranyl pyrophosphate synthase ERG20, endogenous squalene synthetase ERG9, epoxy squalene cyclization enzyme ERG1 and the like are integrated at a site Exg1 of a saccharomyces cerevisiae genome. The yield of MG-V synthesized by shake flask fermentation of the saccharomyces cerevisiae engineering bacteria constructed by the invention reaches 117.6 mg / L, and the saccharomyces cerevisiae engineering bacteria have the advantages of high yield, strong metabolic flux directionality, wide industrial application prospect and the like.

The present invention relates to a sweetener concentrate composition comprising erythritol, one or more steviosides, sucralose, a siraitia grosvenorii extract containing at least 45% by mass of mogroside V, acid, siraitia grosvenorii juice, potassium sorbate and water. The invention also relates to a beverage product comprising the sweetener concentrate composition and a method of sweetening a beverage composition.

The invention relates to the field of biological medicines, in particular to application of mogroside in preparation of medicines for treating and / or preventing leucopenia. The invention provides application of mogroside in preparation of a medicine for treating and / or preventing leucopenia. The invention provides a medicine for treating mogroside V and mogroside IIE, and the medicine can obviously increase the level of blood cells such as leukocytes, improve pathological damage of spleen tissues, activate hematopoietic cell lineage and cell cycle signal pathways in leucopenia, especially in the pathological process of rapid reduction of leukocytes in an immunosuppressive state after chemotherapy, so that the treatment effect of the medicine is improved. The aurora kinase B and transferrin receptor gene expression is activated, and the organism immunity is enhanced. Mogroside V and mogroside IIE have the advantages of definite curative effect, low treatment cost and small toxic and side effects when being used for treating leucopenia, and are very suitable for clinical popularization and application.

The invention discloses a saccharomyces cerevisiae genetically engineered bacterium for efficiently synthesizing mogroside V through multi-dimensional cytoplasm adaptability and a construction method of the saccharomyces cerevisiae genetically engineered bacterium. The construction method of the saccharomyces cerevisiae genetically engineered bacterium comprises the following steps: integrating truncated 3-hydroxy-3-methylglutaryl coenzyme A reductase tHMG1, pentenyl pyrophosphate isomerase IDI1, squalene synthetase ERG9, epoxy squalene cyclization enzyme ERG1, choline kinase ScCK, isopentenyl phosphokinase AtIPK, phosphoketolase BbPK, phosphotransacetylase PTA and dihydroxyacetone hydrolase EcHAD at a site of a saccharomyces cerevisiae genome GAL80, and carrying out enzymolysis, so as to obtain the saccharomyces cerevisiae genetically engineered bacterium. The invention relates to a preparation method of a cytochrome P450 enzyme, which comprises the following steps of: preparing a cycloepoxide hydrolase SgEPH3, a cytochrome P450 enzyme CYP87D18 and a cytochrome P450 enzyme reductase AtCPR1; an ABC efflux protein PDR11, a glycosyl transferase UGTMG1, a sucrose synthase Susy and a glycosyl transferase SgUGT94-289-3 are integrated at a site Exg1 of a saccharomyces cerevisiae genome. The saccharomyces cerevisiae genetically engineered bacterium constructed by the invention realizes a higher level of mogroside V yield synthesized from the beginning in microorganisms, and has important industrial application potential.

The invention relates to the technical field of natural product extraction, and particularly discloses a method for extracting active substances in momordica grosvenori by using a deep eutectic solvent. The system comprises a composite solvent constructed by three groups of specific eutectic solvents, namely levulinic acid and glycerol, choline chloride and levulinic acid, and choline chloride and citric acid; the preparation method comprises the following steps: mixing three preferable eutectic solvents according to an equal volume, adjusting the water content, performing ultrasonic-assisted extraction on the active substances in momordica grosvenori, preliminarily optimizing key parameters such as the water content, the material-liquid ratio, the extraction times, the extraction temperature and the extraction time of the extraction process through a single-factor experiment, and further optimizing through a response surface method or a machine learning algorithm. The composite solvent system provided by the invention can be used for synchronously extracting mogroside V, flavone and polysaccharide active ingredients in momordica grosvenori; in addition, the preparation method optimizes key process parameters through machine learning, and has the advantages of high extraction efficiency, good process stability and environmental friendliness.

The present application relates to the field of biological transformation of mogroside, and discloses a method for efficiently biotransforming mogroside V to prepare mogroside III E. A kind of plant endophytic fungus is used to biotransform mogroside V to obtain mogroside III E. The method is simple in operation, and the product has high conversion yield, so it can be used for large-scale preparation of mogroside III E. The method is simple, efficient, safe, green and low in cost, and provides a new method for industrial production, food production and new drug preparation.

The invention relates to the field of compound tea pigments, and discloses a compound tea pigment antioxidant functional beverage and a preparation method thereof. Comprising 0.1%-0.5% of a tea pigment compound, 0.2%-0.3% of a synergistic antioxidant, 0.05%-0.1% of a sweetening agent, 0.1%-0.5% of a taste masking agent, 0.1%-0.3% of a pH regulator, 0.01%-0.05% of a metal chelating agent, 1%-3% of an osmotic pressure regulator, 0.03%-0.15% of a synergistic component and the balance purified water, the synergistic antioxidant comprises 0.05%-0.1% of lycopene and 0.05%-0.2% of N-acetylcysteine, and the sweetening agent comprises 0.05%-0.1% of mogroside V. According to the invention, sodium phytate (0.01-0.05%) is originally applied to efficiently chelate oxidation-promoting metal ions, and trehalose (1-3%) hydrogen bond wrapping and citric acid-sodium citrate buffer system (pH 3.5-5.0) are combined for synergistic protection, so that oxidative degradation of tea pigment is thoroughly inhibited, and after accelerated aging is carried out for 6 months at-40 DEG C, the retention rate of key active ingredients is greater than 95% (1t of a traditional process; and the shelf life is prolonged to 18 months, and the problems of easy browning and efficacy attenuation pain points of products in the industry for a long time are solved.

The application discloses a beta-1, 6-glycosidic bond hydrolytic enzyme and application thereof in traditional Chinese medicine resources. The method screens a key gene sequence with a function of hydrolyzing beta-1, 6-glycosidic bond from a Candida parapsilosis L7 genome, and names the key gene sequence as CoExg1. A gene engineering bacterium capable of efficiently heterologously expressing CoExg1 is constructed by using a molecular cloning technology. After fermentation and enzyme production, an enzyme catalytic reaction system is established, and a traditional Chinese medicine active molecule in mogroside V is directionally converted, beta-1, 6-glycosidic bonds in different regions of a substrate structure are selectively hydrolyzed, and therefore, efficient and phased synthesis of different products such as sianoside I and mogroside IIIE is realized. In addition, CoExg1 can also hydrolyze beta-glycosidic bonds in the structures of icariin and lupeol, and directionally synthesize icariin II and lupeol, thereby providing important technical support for high-value utilization of traditional Chinese medicine resources and quality improvement and efficiency enhancement of traditional Chinese medicine glycosides.

Monk fruit extracts containing mogrol glycosides such as mogroside V may be treated with enzymes under specific reaction conditions to shift distribution of the Siamenoside I reaction product. Modified enzymes are also employed to shift Siamenoside I distribution to increase yield of Siamenoside I and reduce reaction contaminants. Methods of purifying bioconversion reaction product are also described. Siamenoside I obtained using these methods is a useful sweetener and flavor enhancer for food and beverage compositions and the like.

The present invention relates to an engineered yeast capable of producing mogrol, siamenoside I, mogroside IIIX, mogroside IVA, and / or mogroside V and the use thereof. The present invention provides an engineered yeast capable of producing mogrol, siamenoside I, mogroside IIIX, mogroside IVA, and / or mogroside V. By optimizing and modifying chassis cells, a metabolic pathway of microorganisms is changed, or an expression level of related genes is regulated, thereby enhancing the synthesis efficiency and yield of target products, while improving the production efficiency.

This invention discloses a method for extracting mogroside V, relating to the field of biotechnology. The method involves culturing, fermenting, centrifuging, and homogenizing *E. coli* containing glycosyltransferases UGT-MS1 and UGT-MS2 to obtain an enzyme supernatant. Then, mogroside IIE, uridine diphosphate glucose, the enzyme supernatant, and salt are added to a phosphate buffer solution for enzymatic catalysis to obtain a conversion solution. Finally, the solution is ultrafiltered, loaded onto a column, eluted, and then passed through an alkaline anion exchange resin. The effluent is concentrated and dried to obtain mogroside V. The product has a high yield and is environmentally friendly.

The invention relates to a sweetened composition, in particular to a sweetened composition and a preparation method and use thereof, the sweetened composition consists of at least 0-99% mogroside V and 0-99% fructooligosaccharide, and the preparation method includes the following steps: take Momordica grosvenori extract, then perform enzymatic conversion treatment on the Momordica grosvenori extract by biological enzyme coupled membrane separation technology, convert sucrose contained in Momordica grosvenori into oligofructose under the action of fructosyltransferase, sucrase and glucose isomerase, convert low-sweetness glucose commonly existing in the Momordica grosvenori into high-sweetness fructose, and obtain the sweetened composition after recombination, concentration and sterilization. The sweetened composition product prepared by the invention improves the defects of insufficient sweetness and delayed sweetness of mogroside V, and can be used for preparation of food, beverages, dietary supplements, pharmaceuticals, and pet food.

Methods of producing sweet mogroside compounds via a biotechnological process are provided.SOLUTION: The present invention provides host cells and methods for producing mogrol glycosides, such as mogroside V (Mog. V), mogroside VI (Mog. VI), iso-mogroside V (Isomog. V), siamenoside, and glycosylation products that are minor products of Siraitiagrosvenorii. The present invention provides genetically engineered enzymes and genetically engineered host cells that produce mogrol glycosylation products, such as Mog. V, Mog. VI, and Isomog. V, in high purity and / or high yield. Further, the present technology provides methods of making products, such as foods, beverages, oral care products, sweeteners, and flavors, comprising mogrol glycosides, such as Mog. V, Mog. VI, and Isomog. V.SELECTED DRAWING: None